About US
Contact us
-
AstraZeneca’s type 2 diabetes treatment Xigduo XR obtains FDA approvalBritish-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2 diabetes. Xigduo XR is a combin2014/11/3
-
Pfizer’s Trumenba gets FDA accelerated approval to treat Meningococcal B diseaseUS-based drugmaker Pfizer has received accelerated approval from US Food and Drug Administration (FDA) for its Trumenba to treat Meningococcal B disease in adolescents and young adults. As part of th2014/11/3
-
Qiagen and Astellas Pharma to develop companion diagnostics for cancer and other diseasesQiagen has signed a master collaboration agreement with global pharmaceutical company Astellas Pharma to develop and commercialise companion diagnostics, combined with the latter's drugs for use in ca2014/10/31
-
GSK launches bronchodilator treatment Incruse Ellipta in UKBritish drug-maker GlaxoSmithKline (GSK) has introduced a new once-daily bronchodilator treatment, Incruse Ellipta (umeclidinium) in the UK. A long-acting muscarinic antagonist (LAMA), Incruse has be2014/10/31
-
Johnson & Johnson unveils Asia Pacific Innovation Center in Shanghai, ChinaJohnson & Johnson Innovation has launched the Asia Pacific Innovation Center in Shanghai, China, with satellites in Singapore, Australia and Japan. The new centre will boost Johnson & Johnson2014/10/31
-
Merck’s Keytruda receives FDA breakthrough therapy designation to treat NSCLCMerck has received breakthrough therapy designation from US Food and Drug Administration (FDA) for its Keytruda (pembrolizumab) to treat patients with epidermal growth factor receptor (EGFR) mutation-2014/10/30
-
EU IMI launches new consortium to develop economic models for pharmaceutical industryA new European consortium Driving Reinvestment in research and development and Responsible Antibiotic Use (Drive AB) has been launched, to deal with the growing global threat of antibiotic resistance.2014/10/30
-
International Aspirin Foundation introduces two biennial awardsIn celebration of the 40th anniversary of the formation of The International Aspirin Foundation, we are delighted to announce the introduction of two biennial awards; a Senior Science Award and a Youn2014/10/30
-
Australia’s CSL to buy Novartis influenza vaccine business for $275mAustralia-based CSL has signed an agreement to acquire the global influenza vaccine business from Swiss drug-maker Novartis, for $275m. CSL will include the acquired business in its subsidiary bioCSL2014/10/29
-
Life science investment in Northern England: an interview with Dr Geoff Davison, CEO, BionowCurrently, what are the main challenges around investment in the biomedical and life science sectors across Northern England? There are a number of challenges, but primarily, it's access to funding.2014/10/29